U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587983) titled 'Real-World Treatment of ADC-Resistant HER2-Low Advanced Breast Cancer' on April 14.
Brief Summary: This is a multicenter, retrospective real-world study aiming to evaluate the efficacy and safety of post-antibody-drug conjugate (post-ADC) treatment strategies in patients with HER2-low advanced breast cancer who have developed resistance to prior ADC therapy. The study plans to enroll approximately 220 eligible patients from three centers in China (Jiangsu Province Hospital, Nanjing Drum Tower Hospital, and Nanjing General Hospital of Nanjing Military Command) between January 2018 and December 2025. Key efficacy outcomes include progr...